Search results for "Claudins"

showing 10 items of 11 documents

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric …

2021

Claudin 18.2 (CLDN18.2) is contained within normal gastric mucosa epithelial tight junctions; upon malignant transformation, CLDN18.2 epitopes become exposed. Zolbetuximab, a chimeric monoclonal antibody, mediates specific killing of CLDN18.2-positive cells through immune effector mechanisms.The FAST study enrolled advanced gastric/gastro-oesophageal junction and oesophageal adenocarcinoma patients (aged ≥18 years) with moderate-to-strong CLDN18.2 expression in ≥40% tumour cells. Patients received first-line epirubicin + oxaliplatin + capecitabine (EOX, arm 1, n = 84) every 3 weeks (Q3W), or zolbetuximab + EOX (loading dose, 800 mg/mIn the overall population, both PFS [hazard ratio (HR) = 0…

0301 basic medicineAdultmedicine.medical_specialtyAdolescentEsophageal NeoplasmsPopulationMedizinPhases of clinical researchAdenocarcinomaGastroenterologyLoading doseCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationCapecitabineeducation.field_of_studybusiness.industryHazard ratioAntibodies MonoclonalHematologyOxaliplatin030104 developmental biologyOncology030220 oncology & carcinogenesisClaudinsEsophagogastric Junctionbusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

A genome-wide association study of corneal astigmatism: The CREAM Consortium

2018

Contains fulltext : 191261.pdf (Publisher’s version ) (Open Access) Purpose: To identify genes and genetic markers associated with corneal astigmatism. Methods: A meta-analysis of genome-wide association studies (GWASs) of corneal astigmatism undertaken for 14 European ancestry (n=22,250) and 8 Asian ancestry (n=9,120) cohorts was performed by the Consortium for Refractive Error and Myopia. Cases were defined as having >0.75 diopters of corneal astigmatism. Subsequent gene-based and gene-set analyses of the meta-analyzed results of European ancestry cohorts were performed using VEGAS2 and MAGMA software. Additionally, estimates of single nucleotide polymorphism (SNP)-based heritability for …

0301 basic medicineReceptor Platelet-Derived Growth Factor alphaAcid PhosphataseGene Expression610 Medicine & healthbiomarkkeritPolymorphism Single NucleotideWhite PeopleSensory disorders Donders Center for Medical Neuroscience [Radboudumc 12]Corneal DiseasesCohort StudiesCornea03 medical and health sciences0302 clinical medicineAsian PeopleOdds RatioHumansGenetic Predisposition to Disease610 Medicine & healthsarveiskalvogeenitIntracellular Signaling Peptides and ProteinsAstigmatism030104 developmental biologysilmätauditClaudinsgenetic markers030221 ophthalmology & optometrycorneal astigmatismSoftwaresilmätResearch ArticleGenome-Wide Association Study
researchProduct

Franceschetti Hereditary Recurrent Corneal Erosion

2011

To describe new affected individuals of Franceschetti's original pedigree of hereditary recurrent erosion and to classify a unique entity called Franceschetti corneal dystrophy.Observational case series.Slit-lamp examination of 10 affected individuals was conducted. Biomicroscopic examinations were supplemented by peripheral corneal biopsy in 1 affected patient with corneal haze. Tissue was processed for light and electron microscopy and immunohistochemistry was performed. DNA analysis was carried out in 12 affected and 3 nonaffected family members.All affected individuals suffered from severe ocular pain in the first decade of life, attributable to recurrent corneal erosions. Six adult pat…

AdultMalemedicine.medical_specialtyBiopsyDNA Mutational AnalysisDermatan SulfateCorneal dystrophyCorneal OpacityCorneal erosionAntigens NeoplasmRecurrenceTransforming Growth Factor betaOphthalmologymedicineEye PainHumansChildAgedAged 80 and overCorneal Dystrophies HereditaryExtracellular Matrix Proteinsbusiness.industryCadherinsmedicine.diseaseImmunohistochemistryPedigreeRecurrent corneal erosionOphthalmologyClaudinsFemaleDecorinbusinessCell Adhesion MoleculesChondroitinBiomarkersAmerican Journal of Ophthalmology
researchProduct

Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the…

2011

Abstract Strategies for antibody-mediated cancer immunotherapy, such as active immunization with virus-like particle (VLP)-based vaccines, are gaining increasing attention. We developed chimeric hepatitis B virus core antigen (HBcAg)-VLPs that display a surface epitope of the highly selective tumor-associated cell lineage marker claudin-18 isoform 2 (CLDN18.2) flanked by a mobility-increasing linker. Auto-antibodies elicited by immunization with these chimeric HBcAg-VLPs in 2 relevant species (mouse and rabbit) bind with high precision to native CLDN18.2 at physiologic densities on the surface of living cells but not to the corresponding epitope of the CLDN18.1 splice variant that differs b…

Cancer ResearchHepatitis B virusLung Neoplasmsmedicine.medical_treatmentMolecular Sequence DataCHO CellsAdenocarcinomaActive immunizationCancer VaccinesEpitopeMiceCricetulusAntigenVirus-like particleCancer immunotherapyAntibody SpecificityStomach NeoplasmsCell Line TumorCricetinaemedicineAnimalsHumansProtein IsoformsAmino Acid SequenceVaccines Virus-Like ParticleAutoantibodiesMice Inbred BALB Cbiologybusiness.industryAntibody-Dependent Cell CytotoxicityMembrane ProteinsVirologyMolecular biologyHepatitis B Core AntigensHBcAgHEK293 CellsOncologyCell cultureClaudinsbiology.proteinRabbitsAntibodybusinessCancer research
researchProduct

Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development

2008

Abstract Purpose: Antibody-based cancer therapies have emerged as the most promising therapeutics in oncology. The purpose of this study was to discover novel targets for therapeutic antibodies in solid cancer. Experimental Design: We combined data mining and wet-bench experiments to identify strictly gastrocyte lineage–specific cell surface molecules and to validate them as therapeutic antibody targets. Results: We identified isoform 2 of the tight junction molecule claudin-18 (CLDN18.2) as a highly selective cell lineage marker. Its expression in normal tissues is strictly confined to differentiated epithelial cells of the gastric mucosa, but it is absent from the gastric stem cell zone. …

Cancer ResearchPathologymedicine.medical_specialtymicemedicine.drug_classMolecular Sequence DataGene ExpressionBiologyMonoclonal antibodyMalignant transformationAntigenmedicineProtein IsoformsAnimalsHumansNeoplasms Glandular and EpithelialMembrane Proteins/geneticsAntibodies Monoclonal/immunologyProtein Isoforms/immunologyBase SequenceReverse Transcriptase Polymerase Chain ReactionNeoplasms Glandular and Epithelial/drug therapyAntibodies MonoclonalImmunotherapy ActiveMembrane ProteinsCancermedicine.diseaseFlow CytometryImmunohistochemistryImmunotherapy Active/methodsOncologyCancer cellClaudinsbiology.proteinCancer researchImmunohistochemistryAntibodyStem cell
researchProduct

Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.

2019

CLDN18.2 expression is highly prevalent in Japanese patients with gastric cancer, making it a targetable alteration, and supporting development of zolbetuximab as a therapeutic agent for this patient population.

Cancer Researchmedicine.medical_specialtymedicine.medical_treatmentPopulationprevalenceAdenocarcinomaGastroenterologyAsian PeopleStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingeducationLymph nodeIMAB362Chemotherapyeducation.field_of_studybiologybusiness.industrygastric cancerCancerAntibodies MonoclonalbiomarkersGeneral Medicinemedicine.diseaseImmunohistochemistryClaudinGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyLymphatic MetastasisClaudinsbiology.proteinImmunohistochemistryBiomarker (medicine)Original ArticleAntibodybusinessJapanese journal of clinical oncology
researchProduct

Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals

2011

Claudin-18 isoform 2 (CLDN18.2) is one of the few members of the human claudin family of tight junction molecules with strict restriction to one cell lineage. The objective of the current study was to compare molecular structure and tissue distribution of this gastrocyte specific molecule in mammals. We show here that the CLDN18.2 protein sequence is highly conserved, in particular with regard to functionally relevant domains in mouse, rat, rabbit, dog, monkey and human and also in lizards. Moreover, promoter regions of orthologs are highly homologous, including the binding site of the transcription factor cyclic AMP-responsive element binding protein (CREB), which is known to regulate acti…

Gene isoformmiceMolecular Sequence DataGene Expressionmolecular structureMammals/geneticsBiologyphylogenyRATSConserved sequenceEvolution MolecularDogsProtein Isoforms/geneticsSequence Homology Nucleic AcidGene expressionGeneticsProtein IsoformsAnimalsTissue DistributionAmino Acid SequenceMembrane Proteins/geneticsBinding sitePromoter Regions GeneticClaudinGeneTranscription factorConserved SequenceGastric Mucosa/metabolismMammalsRegulation of gene expressionGeneticsBinding SitesBase SequenceStomachStomach/cytologyMembrane ProteinsCREB-Binding Protein/metabolismHaplorhiniGeneral MedicineCREB-Binding ProteinGene Expression RegulationGastric MucosaOrgan SpecificityMultigene FamilyClaudinsRabbitsGene
researchProduct

The importance of tight junctions in the blood-brain barrier

2021

There are two barriers in the central nervous system (CNS) responsible for maintaining the homeostatic balance of the human body’s internal environment in relation to external conditions: the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB). The blood-brain barrier is a physical barrier with a fixed location between the blood and the nervous tissue. Its basic structural elements include endothelial cells of the brain capillaries, astrocytes and pericytes. The blood-brain barrier is the barrier between the blood and neurons which isolates the central nervous system from the rest of the body in a unique manner. The blood-brain barrier is formed by astrocytes and per…

Inorganic Chemistrytight junctionsEcologyHealth Toxicology and Mutagenesisintercellular connectionsactive transportblood-brain barriercentral nervous systemclaudinsPollutionJournal of Elementology
researchProduct

Caspase-3 contributes to ZO-1 and Cl-5 tight-junction disruption in rapid anoxic neurovascular unit damage.

2011

BACKGROUND: Tight-junction (TJ) protein degradation is a decisive step in hypoxic blood-brain barrier (BBB) breakdown in stroke. In this study we elucidated the impact of acute cerebral ischemia on TJ protein arrangement and the role of the apoptotic effector protease caspase-3 in this context. METHODOLOGY/PRINCIPAL FINDINGS: We used an in vitro model of the neurovascular unit and the guinea pig whole brain preparation to analyze with immunohistochemical methods the BBB properties and neurovascular integrity. In both methodological approaches we observed rapid TJ protein disruptions after 30 min of oxygen and glucose deprivation or middle cerebral artery occlusion, which were accompanied by…

Time FactorsAnatomy and Physiologylcsh:MedicineMiceMolecular Cell BiologyPathologySignaling in Cellular ProcessesHypoxia Brainlcsh:ScienceCells CulturedNeuropathologyApoptotic SignalingMultidisciplinaryTight junctionCaspase 3ChemistryAnimal ModelsCell biologyTransport proteinProtein Transportmedicine.anatomical_structureNeurologyBlood-Brain BarrierMedicineResearch ArticleSignal TransductionClinical Research DesignCerebrovascular DiseasesGuinea PigsIschemiaContext (language use)Caspase 3Protein degradationBlood–brain barrierNeurological SystemTight JunctionsCapillary PermeabilityModel OrganismsDiagnostic MedicinemedicineAnimalsTransient Ischemic AttacksAnimal Models of DiseaseClaudinBiologyIschemic Strokelcsh:REndothelial CellsMembrane ProteinsPhosphoproteinsmedicine.diseaseAnatomical PathologyClaudinsImmunologyZonula Occludens-1 ProteinNervous System Componentslcsh:QPLoS ONE
researchProduct

An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors.

2019

A one-two, CAR-T cell punch Chimeric antigen receptor (CAR)–T cells have been clinically effective in killing certain hematological malignancies, but achieving long-term patient responses for solid tumors remains a challenge. Reinhard et al. describe a two-part “CARVac” strategy to overcome poor CAR-T cell stimulation and responses in vivo. They introduce the tight junction protein claudin 6 (CLDN6) as a new CAR-T cell target and designed a nanoparticulate RNA vaccine encoding a chimeric receptor directed toward CLDN6. This lipoplex RNA vaccine promotes CLDN6 expression on the surface of dendritic cells, which in turn stimulates and enhances the efficacy of CLDN6-CAR-T cells for improved tu…

medicine.medical_treatmentT-LymphocytesCellCancer VaccinesImmunotherapy AdoptiveMiceAntigenmedicineAnimalsHumansClaudinB cellMice Inbred BALB CVaccines SyntheticMultidisciplinaryReceptors Chimeric AntigenTight junctionChemistryRNAImmunotherapyChimeric antigen receptorMice Inbred C57BLmedicine.anatomical_structureClaudinsCancer researchRNAFemaleScience (New York, N.Y.)
researchProduct